tranilast inn brand name rizaben antiallergic drug developed kissei pharmaceuticals approved use japan south korea bronchial asthma indications keloid hypertrophic scar added used japan south korea china treat asthma keloid scars hypertrophic scars ophthalmic solution allergic pink taken women might become pregnant secreted breast people taking warfarin also take tranilast appears inhibit interfere metabolism drugs affected given systemically tranilast appears cause liver damage large wellconducted clinical trial caused elevated transaminases three times upper limit normal percent patients well anemia kidney failure rash problems given systemically inhibits blood formation causing leukopenia thrombocytopenia march marketed japan china south korea brand names ao te min arenist brecrus garesirol hustigen krix lumios rizaben tramelas tranilast marketed combination drug salbutamol brand name shun fda proposed tranilast excluded list active pharmaceutical ingredients compounding pharmacies us could formulate appears work inhibiting release histamine mast cells found inhibit proliferation fibroblasts biological target shown inhibit release many cytokines various cell types vitro also shown inhibit inflammasome activation studied treatment inflammatory also found block ion channel tranilast analog metabolite tryptophan chemical name anthranilic acid almost insoluble water easily soluble dimethylsulfoxide soluble dioxane slightly soluble ether photochemically unstable promising results three small clinical trials tranilast studied major clinical trial presto trial smithkline beecham partnership kissei prevention restenosis percutaneous transluminal coronary found effective altacor developing formulation tranilast prevent scarring following glaucoma surgery obtained orphan designation ema developed kissei first approved japan south korea asthma approved uses keloid hypertrophic scars added later httpsenwikipediaorgwikitranilast